ライフサイエンスコーパス: multinational

1 bservational Program (TOP) is an open-label, multinational, 10-year prospective study in clinical pra

2 31) in a 26-week open-label, parallel-group, multinational (15 countries) study.

3 att hours/square meters/day) on the basis of multinational and cross-state studies.

4 Herein, a multinational and multidisciplinary panel of neuro-oncol

5 m two multiple sclerosis registries, MSBase (multinational) and OFSEP (French), were used.

6 al Arabidopsis community, represented by the Multinational Arabidopsis Steering Committee (MASC), has

7 Talcott, 0.721 (95% CI, 0.669 to 0.768) for Multinational Association for Supportive Care in Cancer

8 low risk of complications as predicted by a Multinational Association for Supportive Care in Cancer

9 t beginning with a validated risk index (eg, Multinational Association for Supportive Care in Cancer

10 ary, and meeting materials from ASCO and the Multinational Association for Supportive Care in Cancer

11 Multinational Association of Supportive Care in Cancer/I

12 ients) and online anonymized surveys of 1225 multinational BC patients and survivors were also conduc

13 on outcomes were compared in the prospective multinational Berlin-Frankfurt-Muenster (BFM) study grou

14 We identify critical habitats across multinational boundaries and show that top predators exp

15 ion of patient-reported outcomes (PROs) into multinational cancer clinical trials in the cancer coope

16 evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 1

17 ence is to develop prospective, national and multinational case registries to determine the range of

18 We performed a multinational case-control study that included 51 kidney

19 emergence of Asian retail developing-country multinational chains.

20 zole in a Phase 3, randomized, double-blind, multinational clinical trial for the primary treatment o

21 andomized, double-blind, placebo-controlled, multinational clinical trial of 6560 patients within 48

22 were assessed for 816 patients enrolled in a multinational clinical trial of artemisinin combination

23 andomized, double-blind, placebo-controlled, multinational clinical trial with a 24-week treatment pe

24 ur data set was prospectively collected in a multinational clinical trial, videos rather than still i

25 In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (

26 ed and validated in rigorous multicenter and multinational clinical trials aimed at gaining regulator

27 eumonia (HAP) enrolled in two registrational multinational clinical trials for the genetic elements c

28 h Network stage F3 or F4) were enrolled in 4 multinational clinical trials of simtuzumab and selonser

29 clerosis (SSc)-related digital ulcers in two multinational clinical trials; and although statin thera

30 We analysed an independent multinational cohort comprising 3100 patients with neuro

31 Our study had a multinational cohort design, using population-based data

32 QBB is a multinational cohort including 33 different nationalitie

33 ep learning algorithms, trained in a diverse multinational cohort of 1280 patients to localize pariet

34 rithm were assessed by blinded analysis of a multinational cohort of 834 patients with molecularly co

35 In a multinational cohort of AHF, we examined the ability of

36 In a multinational cohort of critically ill children with sev

37 incident HPV infections to GW detection in a multinational cohort of men aged 18-70 years.

38 Using a prospective, multinational cohort of patients with definite NVE, the

39 characterize the 135kb SNCA locus in a large multinational cohort of patients with PD, PDD, and DLB a

40 In this prospective, multinational cohort of patients with S. aureus PVIE, EV

41 In a multinational cohort of patients with stable angina, the

42 thogenesis of food allergies and multicenter-multinational cohort studies will elucidate interactions

43 This retrospective multinational cohort study included patients from 25 oph

44 In this prospective multinational cohort study on 69,066 participants (on av

45 Registry of Acute Coronary Events (GRACE), a multinational cohort study, 44 372 patients with an ACS

46 In this large, prospective, multinational cohort, more than one half of all cases of

47 e, and loss to follow-up were from published multinational cohorts in low-income and middle-income co

48 implemented in 2002 after its validation in multinational cohorts including patients from cancer cen

49 rker field in FTD, but the creation of large multinational cohorts is facilitating better powered stu

50 lity following HIV seroconversion in a large multinational collaboration of HIV seroconverter cohorts

51 GBD, an ongoing multinational collaboration to provide comparable and co

52 We performed a multinational collaborative study, which included assess

53 Using a multinational collection of isolates from methicillin-re

54 Using multinational collections of methicillin-susceptible Sta

55 compare female versus male VIPs in a large, multinational collective of VIPs with regards to outcome

56 We randomly assigned 878 employees of a multinational company based in the United States to rece

57 A multinational consensus meeting of multidisciplinary exp

58 Multinational conservation initiatives that prioritize i

59 brain and intracranial volumes from a large multinational consortium.

60 carditis-Microbiology, a large, multicenter, multinational consortium.

61 In this review, we summarize the progress of multinational control initiatives against Chagas disease

62 Multinational corporations play a prominent role in shap

63 cluding integrated 'keystone actors' such as multinational corporations.

64 Nine registries had multinational coverage, whereas 48 were national registr

65 o objectively track sleep-wake dynamics in a multinational crew of six during 520 d of confined isola

66 A multinational cross-sectional study of children with ARP

67 In this multinational cross-sectional study, 322 physicians from

68 In this multinational cross-sectional study, existing data on 4,

69 the Acute Hospital Care Setting) study is a multinational cross-sectional survey designed to assess

70 In this multinational, cross-sectional, observational cohort stu

71 e first prospectively declared collaborative multinational database, including individual data of pat

72 This multinational Delphi survey represents the first expert-

73 Between July, 2008, and June, 2010, we did a multinational double-blind, randomised, phase 2 study co

74 In this multinational, double-blind, 24 week study, we enrolled

75 SOLID-TIMI 52 was a multinational, double-blind, placebo-controlled trial th

76 sistant prostate cancer were enrolled into a multinational, double-blind, placebo-controlled trial.

77 We did this randomised, multinational, double-blind, placebo-controlled, phase 2

78 In this phase 3, multinational, double-blind, randomised controlled trial

79 In this phase 3, multinational, double-blind, randomised, controlled tria

80 EORTC 18071 was a multinational, double-blind, randomised, phase 3 trial i

81 In the multinational, double-blind, randomized LEADER trial, 9,

82 DESIGN, SETTING, AND PARTICIPANTS: Multinational, double-blind, randomized placebo-controll

83 In this multinational, double-blind, randomized trial, we compar

84 Here we describe a multinational drug discovery programme that has delivere

85 Aggregate data from a multinational effort show that in mothers at high risk o

86 As part of a multinational effort to introduce C4 traits into rice to

87 for 610 Gram-negative bacilli, including 302 multinational Enterobacterales isolates with characteriz

88 on controlled modes and enrolled in a large, multinational, epidemiological study.

89 The largest multinational European birth cohort study on food allerg

90 The multinational European study recruited 999 patients with

91 We provide a multinational expert consensus on separate hierarchical

92 ically considered the available evidence and multinational expert criticism, revised the Rome II diag

93 a Guideline Panel is a multidisciplinary and multinational group composed of experts in pediatric onc

94 a Guideline Panel is a multidisciplinary and multinational group of experts in pediatric oncology and

95 risk anal human papillomavirus (HPV) among a multinational group of men who have sex with men (MSM) a

96 five years of implementation (2008-2013) of multinational health adaptation projects in Albania, Bar

97 lidity and improve instrument reliability in multinational health services research studies involving

98 ted within the HPV Infection in Men Study, a multinational HPV cohort study.

99 The Paris Agreement is a multinational initiative to combat climate change by kee

100 [CAFs]) using wholesale data from the IQVIA-Multinational Integrated Data Analysis System database,

101 is research included building linkages among multinational, interdisciplinary team members, generatin

102 In the main publication of the multinational Interphone Study, investigators concluded

103 Multinational investigation of fracture risk with antide

104 The ongoing multinational Justification for the Use of statins in Pr

105 We conducted six parallel, multinational lipid-lowering trials enrolling 4300 patie

106 T1-genotyped subjects with 34 mutations from multinational long QT syndrome registries were studied.

107 examined in 3,386 genotyped subjects from 7 multinational LQTS registries, categorized as LQTS with

108 We also surveyed three multinational manufacturers who supply influenza vaccine

109 s from relative risk estimates reported in a multinational meta-analysis.

110 al study of cardiovascular risk factors (the Multinational mONItoring of trends and determinants in C

111 ], Gutenberg Health Study [GHS; n=4354], and Multinational Monitoring of Trends and Determinants in C

112 This was a multinational, multi-institutional, retrospective study.

113 ients were retrospectively included from the multinational multicenter European Society of Cardiovasc

114 centers, that had participated in a 6-month multinational multicenter randomized clinical trial (RCT

115 national Forum of Ophthalmic Simulation is a multinational, multicenter collaborative established to

116 The present observational, prospective, multinational, multicenter study determined the minimal

117 This was a multinational, multicenter study of 182 CSU patients.

118 Phase 3, multinational, multicenter, 26-week, randomized, open-la

119 FORWARD) study is a prospective, single-arm, multinational, multicenter, observational study.

120 urvival as part of the Global Fluid Study, a multinational, multicenter, prospective, combined incide

121 -paroxysmal atrial fibrillation is the first multinational, multicenter, prospective, noninferiority

122 This was an 8-week multinational, multicenter, randomized, double-blind, pl

123 E5 inhibitor, PF-00489791, was assessed in a multinational, multicenter, randomized, double-blind, pl

124 We conducted a multinational, multicenter, retrospective cohort study,

125 A multinational, multicentre retrospective cohort study, c

126 NP SINUS-24 and LIBERTY NP SINUS-52 were two multinational, multicentre, randomised, double-blind, pl

127 ond largest kingdom of eukaryotic life, by a multinational, multilaboratory consortium.

128 Our objective was to create a multinational, multistakeholder-recommended pediatric cr

129 EXPLORE is a prospective, multinational, natural history study characterizing dise

130 In spite of the multinational nature of the study, sample size is a limi

131 We conducted a large, randomized, multinational, noninferiority trial to determine whether

132 onfounding are potential limitations of such multinational observational registries.

133 This multinational observational retrospective population-bas

134 In a multinational observational study of adult patients hosp

135 In this multinational observational study, improvements in the m

136 s and their clinical isolates collected in a multinational, observational cohort study to determine i

137 This multinational, open-label study included 10 adults with

138 perinatal or infantile hypophosphatasia in a multinational, open-label study of treatment with ENB-00

139 In this phase 3, randomised, multinational, open-label, non-inferiority trial, we enr

140 SADAL was a multicentre, multinational, open-label, phase 2b study done in 59 sit

141 The present study was a multinational, open-label, single-arm, phase 3 prophylax

142 Of the 53 experts invited to participate, a multinational panel of 35 (66%) individuals with a mean

143 ADVICE4U was a six-month, multicenter, multinational, parallel, randomized controlled, non-infe

144 ve, observational, Internet-based study with multinational participation included 197 ophthalmic clin

145 rom in-depth statistical analysis of a large multinational patient cohort.

146 In a large multinational PE registry, variations were observed in t

147 This was a prospective, multinational pharmacokinetic point-prevalence study inc

148 IMPAACT P1115 is a multinational phase 1/2 proof-of-concept study in which

149 is randomised, double-blind, parallel-group, multinational phase 3 study, patients aged 70 years or o

150 This multinational phase 3 trial involved adults who had acti

151 We conducted a double-blind, multinational phase IIb trial of 556 men and women with

152 ective in this population than is implied by multinational phase III controlled trials.

153 Data were analyzed from a large, randomized, multinational phase III registration trial involving 271

154 A pivotal multinational phase III trial of the Biopure product HBO

155 ouble-blind, placebo-controlled, randomized, multinational phase III trial, 1,144 patients with human

156 solates from patients enrolled in two large, multinational phase three clinical trials assessing tela

157 In a multinational, phase 2, dose-finding study and extension

158 TRINOVA-3, a multicentre, multinational, phase 3, double-blind study, was done at

159 ated pneumonia, compared with meropenem in a multinational, phase 3, double-blind, non-inferiority tr

160 A multinational, phase 3, double-blind, placebo-controlled

161 In this multinational, phase 3, observer-blinded study, we rando

162 on-inferiority, parallel-group, multicentre, multinational, phase 3a trial (SUSTAIN 4) at 196 sites i

163 A multinational, phase III trial (SYMMETRY) of E + P compa

164 andomized, double-blind, placebo-controlled, multinational, phase III trial included adults with a hi

165 ta from two ongoing, randomised, open-label, multinational, phase III, RESIST studies.

166 We conducted a multinational placebo-controlled trial, in which 1195 pa

167 In an ongoing multinational, placebo-controlled, observer-blinded, piv

168 Multinational, population-based cohort study including i

169 0 asthmatic children aged 4-6 years from the multinational PreDicta cohort were prospectively followe

170 The authors initiated a multinational program to implement cardiac pacing in 14

171 A multinational program was initiated in 1983 to provide t

172 and funding, not least because of ambitious multinational projects that aim to increase crop yields

173 In this baseline assessment of a multinational prospective cohort study (the Assessment o

174 The PANORAMA study was a multinational prospective cohort study at tertiary hospi

175 ve Urban Rural Epidemiology study is a large multinational prospective cohort study of adults aged 35

176 The study was nested within a multinational prospective HPV natural history study of m

177 This was a multinational prospective multicenter observational stud

178 METHODS AND We conducted a multinational prospective observational longitudinal stu

179 TRACK-HD is a multinational prospective observational study of Hunting

180 In this multinational, prospective cohort study, we examined ass

181 There is a lack of multinational, prospective data characterizing the disea

182 SIGN, SETTINGS, AND PATIENTS: A multicenter, multinational, prospective management outcome study in 1

183 In two multicenter, multinational, prospective observational studies, a cent

184 which began >10 years ago, is an open-label, multinational, prospective observational study evaluatin

185 We conducted a multinational, prospective study involving patients admi

186 FRAILTY-AVR was a multinational, prospective, observational cohort assembl

187 in Chronic Heart Failure) is a multicenter, multinational, prospective, observational study that inc

188 d subsequent overall survival (OS) in large, multinational PTCL cohorts.

189 In this phase 3, multicenter, multinational, randomised controlled trial, we included

190 These data support the initiation of a multinational, randomised, controlled trial of intrathec

191 SPORT) included in this pooled analysis were multinational, randomised, double-blind, placebo-control

192 We did this multinational, randomised, double-blind, placebo-control

193 cal data collected in the ARISTOTLE trial, a multinational randomized clinical trial that observed 18

194 bloodstream isolates collected as part of a multinational randomized clinical trial, USA 300 and pvl

195 A prospective, multinational randomized controlled trial (RCT) and a co

196 gies through large well designed multicentre-multinational randomized controlled trials incorporating

197 The Mainsail trial was a multinational randomized phase 3 study of 1059 patients

198 on of Angiotensin II Antagonist Losartan), a multinational randomized trial in symptomatic patients w

199 36 cases, 234 controls]) was nested within a multinational randomized trial of ART efficacy (Prospect

200 ombolysis in Myocardial Infarction 48) was a multinational randomized trial of the oral factor Xa inh

201 We report the results of a multinational randomized, double-blind study, in which p

202 d in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) randomized clinical trial between January

203 Multinational, randomized clinical trial conducted at 20

204 ance and subtype with virologic failure in a multinational, randomized clinical trial that evaluated

205 Cancer of the Endometrium (LACE) trial was a multinational, randomized equivalence trial conducted be

206 This double-blind, placebo-controlled, multinational, randomized study included 116 subjects di

207 We conducted a multinational, randomized study to compare radiotherapy

208 INOVATE-HF was a multinational, randomized trial involving 85 centers inc

209 In this multicenter, multinational, randomized, crossover trial, we assessed

210 l was a secondary objective of COU-AA-301, a multinational, randomized, double-blind phase III trial

211 ombolysis In Myocardial Infarction 50) was a multinational, randomized, double-blind, placebo-control

212 This was a multinational, randomized, investigator-initiated, open-

213 e Questionnaire (MLHFQ) was used in a large, multinational, randomized, placebo-controlled trial to m

214 hich is complex and difficult to quantify, a multinational REDD+ program for a region could address l

215 We did a multinational registry analysis of the use of hydroxychl

216 The aim of this multinational registry is to present a real-world overvi

217 The data were collected by PAIN OUT, a multinational registry project established by the Europe

218 by expert panels of a number of national and multinational regulatory bodies, including the US, the E

219 ltidisciplinary and increasingly cooperative multinational research effort.

220 A multinational retrospective cohort study of patients wit

221 A multinational retrospective study (9 countries, 25 cente

222 We included in this multinational retrospective study 112 recipients diagnos

223 eristics of PCSK9 GOF mutation carriers in a multinational retrospective, cross-sectional, observatio

224 We did a planned secondary analysis of a multinational, retrospective cohort study of the Pediatr

225 We did a multicentre, multinational, retrospective cohort study using individu

226 This study is a multinational, retrospective review of patients treated

227 This multinational, retrospective study of 2026 DPs involved

228 This multinational, retrospective study of 4301 pancreatoduod

229 lopment of a clinical event using a 10-year, multinational, retrospectively identified RIS dataset.

230 6 weeks, and placebo-treated patients from a multinational sample who subsequently received etanercep

231 aseline, patients with AS in both the US and multinational samples had significantly lower scores tha

232 spectively analyzed records from the ongoing multinational Sarcomeric Human Cardiomyopathy Registry.

233 this trial population, recruited in diverse multinational settings.

234 417 Mycobacterium tuberculosis isolates from multinational sites with a high prevalence of drug resis

235 The prospective multinational SMS (Substrate Modification Study) was des

236 Multiscale, multimethod-and ideally multinational-studies are needed.

237 , we directly test the original methods in a multinational study (n = 4,098 participants, 19 countrie

238 n children 6 months to <10 years of age in a multinational study conducted during 2010-2011.

239 This multinational study from 5 centers demonstrates that LRR

240 enrolled in CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure) and related this t

241 idity with mortality in summer in this large multinational study is counter to expectations from phys

242 CardShock is a prospective European multinational study of cardiogenic shock.

243 Prospective, cross-sectional, multicenter, multinational study of pain intensity associated with 12

244 In this multinational study of patients referred for coronary co

245 In this large multinational study of patients with dilated cardiomyopa

246 on of therapeutic strategies, we conducted a multinational study of the natural history and imaging f

247 andomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreot

248 ajority receiving folic acid) and 62% of the multinational study patients (majority not receiving fol

249 d in 93% of US study patients and 94% of the multinational study patients.

250 Among a multinational study population, 46.5% of participants wi

251 This multicenter multinational study shows lack of phenotypic differences

252 This multinational study shows major concerns in the delivery

253 No multinational study to compare the perceptions of medica

254 We performed a large prospective multinational study to study the ability to remove these

255 The Breathing Not Properly Multinational Study was a seven-center, prospective stud

256 omized, placebo-controlled, parallel-design, multinational study was conducted.

257 The aim of this multinational study was to measure and describe the perc

258 In a multinational study, 519 patients with newly diagnosed c

259 In a cross-sectional, multinational study, all-cause and ASCVD mortality rates

260 In a double-blind phase 2 multinational study, conducted from April 2005 to Octobe

261 In a large prospective multinational study, removal success of FCSEMS after ext

262 In this multinational study, there was variation across countrie

263 In this large multinational study, treatment with SGLT-2i versus other

264 was a phase II, observer-blind, randomized, multinational study.

265 We examined these in a multinational survey.

266 The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial included a prospectively plan

267 follow-up, the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial reported no difference in dis

268 international Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.

269 sboundary conservation potential of securing multinational threatened species varied substantially, t

270 ing samples from 278 patients with CD from a multinational training cohort.

271 omised, open-label, two-arm, parallel-group, multinational, treat-to-target, non-inferiority trial do

272 In a multinational trial (V325), 445 patients were randomly a

273 In this large multinational trial among patients undergoing cardiac su

274 hagocytosis of merozoites were measured in a multinational trial assessing the efficacy of artesunate

275 ascular RisK) is a randomized, double-blind, multinational trial comparing monthly subcutaneous evolo

276 ilure trials, the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Grupp

277 ents enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial (n=1

278 ion with HF from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

279 measured in CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure), could be used to

280 Morbidity], CORONA [Controlled Rosuvastatin Multinational Trial in Heart Failure], and MAGGIC [Meta-

281 of patients from the Controlled Rosuvastatin Multinational Trial in HF (CORONA) study.

282 -REF trials, and the Controlled Rosuvastatin Multinational Trial in HF-REF (CORONA).

283 al report the results of LYM-2034, a phase 2 multinational trial in which 164 patients with nongermin

284 In this multinational trial involving patients with a PFO who ha

285 in the first large randomized, double-blind multinational trial of this therapeutic modality for rag

286 l Infarction 25) study, a large, randomized, multinational trial, demonstrated a reduction in death o

287 In this randomized, double-blind, multinational trial, we assessed the efficacy and safety

288 In a double-blind, multinational trial, we randomly assigned 330 patients w

289 apies were treated in this pivotal phase II, multinational trial.

290 a-2a (40 kd) plus ribavirin in a randomized, multinational trial.

291 Ongoing multinational trials are pursuing whether reducing infla

292 In six multinational trials evaluating bococizumab, antidrug an

293 Two multinational trials were conducted to compare the effic

294 In two parallel, multinational trials with different entry criteria for L

295 on treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) stu

296 y artery disease, and stable angina from the multinational Type 2 Diabetes Evaluation of Ranolazine i

297 Initially, MVP envisioned partnering with a multinational vaccine manufacturer, but the target price

298 rrelates for survival were evaluated using a multinational valve-in-valve registry that included 459

299 es a range of successful strategies from the multinational Vision 2020 Initiative to disease-specific

300 A multinational web-based Delphi survey with a focus on me